These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12505833)

  • 21. omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study.
    Zanarini MC; Frankenburg FR
    Am J Psychiatry; 2003 Jan; 160(1):167-9. PubMed ID: 12505817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treating prodromal episodes to prevent relapse in schizophrenia.
    Herz MI; Glazer W; Mirza M; Mostert M; Hafez H
    Br J Psychiatry Suppl; 1989 Jul; (5):123-7. PubMed ID: 2574984
    [No Abstract]   [Full Text] [Related]  

  • 23. Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment.
    Morrissette DA; Stahl SM
    CNS Spectr; 2012 Nov; 17 Suppl 1():10-21. PubMed ID: 23462201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of Omega-3 Polyunsaturated Fatty Acids as Augmentation Therapy in Treatment-Resistant Schizophrenia.
    Cuéllar-Barboza AB; Sánchez-Ruiz JA; Corral PM
    Prim Care Companion CNS Disord; 2017 May; 19(3):. PubMed ID: 28472557
    [No Abstract]   [Full Text] [Related]  

  • 25. Omega-3 fatty acids and depression: from cellular mechanisms to clinical care.
    Freeman MP; Rapaport MH
    J Clin Psychiatry; 2011 Feb; 72(2):258-9. PubMed ID: 21382308
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of omega-3 fatty acid on platelet serotonin responsivity in patients with schizophrenia.
    Yao JK; Magan S; Sonel AF; Gurklis JA; Sanders R; Reddy RD
    Prostaglandins Leukot Essent Fatty Acids; 2004 Sep; 71(3):171-6. PubMed ID: 15253886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Omega-3 fatty acids in cardiology. Latest developments].
    von Schacky C
    MMW Fortschr Med; 2007 Sep; 149 Suppl 3():97-101. PubMed ID: 17955786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can clinical practice guide a research agenda?
    Marder SR
    Schizophr Bull; 2002; 28(1):127-9. PubMed ID: 12047012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switching antipsychotic medications: a 2-year chart-review study exploring patient characteristics and psychiatric service use of schizophrenia patients.
    Schneider AL; Mosier KE; Tempier RP
    J Clin Psychiatry; 2009 Jun; 70(6):937-9. PubMed ID: 19573492
    [No Abstract]   [Full Text] [Related]  

  • 30. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omega-3 fatty acids: time to get the messages right!
    Calder PC; Deckelbaum RJ
    Curr Opin Clin Nutr Metab Care; 2008 Mar; 11(2):91-3. PubMed ID: 18301081
    [No Abstract]   [Full Text] [Related]  

  • 32. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Heinrichs RW
    Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745
    [No Abstract]   [Full Text] [Related]  

  • 33. Overestimating the prevalence of subtherapeutic dosing of atypical antipsychotics.
    Stensland MD; Ascher-Svanum H; Lawson AH; Conley RR
    J Clin Psychiatry; 2009 Aug; 70(8):1189-90; author reply 1190-91. PubMed ID: 19758530
    [No Abstract]   [Full Text] [Related]  

  • 34. Switch or stay?
    Davis JM; Marder SR; Tamminga CA
    Am J Psychiatry; 2006 Dec; 163(12):2032-3. PubMed ID: 17151147
    [No Abstract]   [Full Text] [Related]  

  • 35. [Quotidien prescription: between references and reality].
    Verdoux H
    Encephale; 2006 Jan; 32 Pt 2():S10-1. PubMed ID: 16800079
    [No Abstract]   [Full Text] [Related]  

  • 36. Sertindole versus haloperidol for schizophrenia.
    Mattes JA
    Am J Psychiatry; 1998 Sep; 155(9):1303; author reply 1303-4. PubMed ID: 9734567
    [No Abstract]   [Full Text] [Related]  

  • 37. The power of 3. Omega-3 fatty acids.
    Mayo Clin Health Lett; 2007 Aug; 25(8):6. PubMed ID: 17715541
    [No Abstract]   [Full Text] [Related]  

  • 38. Omega-3 fatty acids for atypical antipsychotic-associated hypertriglyceridemia.
    Freeman MP; McInerney K; Sosinsky AZ; Kwiatkowski MA; Cohen LS
    Ann Clin Psychiatry; 2015 Aug; 27(3):197-202. PubMed ID: 26247219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE).
    Lieberman JA
    Arch Gen Psychiatry; 2006 Oct; 63(10):1069-72. PubMed ID: 17015808
    [No Abstract]   [Full Text] [Related]  

  • 40. [Acute phase drug therapy and drug switching in the treatment of patients with schizophrenia].
    Fujii Y
    Seishin Shinkeigaku Zasshi; 2001; 103(12):1030-5. PubMed ID: 11925840
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.